Take anti-PD1 immunotherapy as an example, in most advanced cancers, except Hodgkin lymphoma (which has high PD-L1/L2 expression) and melanoma (which has high tumor mutational burden), the objective response rate with anti-PD-1/PD-L1 monotherapy is only ~20%. This evidence concerns the gene PDCD1 and neoplasm.